Prion protein self-interaction in prion disease therapy approaches

被引:1
|
作者
Rigter, Alan [1 ]
Priem, Jan [1 ]
Langeveld, Jan P. M. [1 ]
Bossers, Alex [1 ]
机构
[1] Cent Vet Inst Wageningen UR, Dept Infect Biol, Lelystad, Netherlands
关键词
prion protein; prion; conversion; binding domains; self-interaction; prion disease therapy; CREUTZFELDT-JAKOB-DISEASE; IN-VITRO CONVERSION; SUSCEPTIBILITY-LINKED POLYMORPHISMS; BOVINE SPONGIFORM ENCEPHALOPATHY; NATURAL SCRAPIE; INSERT MUTATION; CELL-CULTURES; PRP GENOTYPES; CLOSED FLOCK; PRNP GENE;
D O I
10.1080/01652176.2011.604976
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Transmissible spongiform encephalopathies (TSEs) or prion diseases are unique disorders that are not caused by infectious micro-organisms (bacteria or fungi), viruses or parasites, but rather seem to be the result of an infectious protein. TSEs are comprised of fatal neurodegenerative disorders affecting both human and animals. Prion diseases cause sponge-like degeneration of neuronal tissue and include (among others) Creutzfeldt-Jacob disease in humans, bovine spongiform encephalopathy (BSE) in cattle and scrapie in sheep. TSEs are characterized by the formation and accumulation of transmissible (infectious) disease-associated protease-resistant prion protein (PrPSc), mainly in tissues of the central nervous system. The exact molecular processes behind the conversion of PrPC into PrPSc are not clearly understood. Correlations between prion protein polymorphisms and disease have been found, however in what way these polymorphisms influence the conversion processes remains an enigma; is stabilization or destabilization of the prion protein the basis for a higher conversion propensity? Apart from the disease-associated polymorphisms of the prion protein, the molecular processes underlying conversion are not understood. There are some notions as to which regions of the prion protein are involved in refolding of PrPC into PrPSc and where the most drastic structural changes take place. Direct interactions between PrPC molecules and/or PrPSc are likely at the basis of conversion, however which specific amino acid domains are involved and to what extent these domains contribute to conversion resistance/sensitivity of the prion protein or the species barrier is still unknown.
引用
收藏
页码:115 / 128
页数:14
相关论文
共 50 条
  • [21] Prion protein misfolding and disease
    Moore, Roger A.
    Taubner, Lara M.
    Priola, Suzette A.
    CURRENT OPINION IN STRUCTURAL BIOLOGY, 2009, 19 (01) : 14 - 22
  • [22] A PERK for the therapy of prion disease
    Charlotte Harrison
    Nature Reviews Drug Discovery, 2013, 12 (12) : 906 - 906
  • [23] Antisense therapy for prion disease
    Alexandra Le Bras
    Lab Animal, 2019, 48 : 330 - 330
  • [24] Prion protein self-peptides modulate prion interactions and conversion
    Rigter, Alan
    Priem, Jan
    Timmers-Parohi, Drophatie
    Langeveld, Jan P. M.
    van Zijderveld, Fred G.
    Bossers, Alex
    BMC BIOCHEMISTRY, 2009, 10
  • [25] Prion protein and Alzheimer disease
    Kellett, Katherine A. B.
    Hooper, Nigel M.
    PRION, 2009, 3 (04) : 190 - 194
  • [26] Interaction of the disease-associated prion protein with quartz surfaces
    Ma, Xin
    McKenzie, Debbie I.
    Aiken, Judd M.
    Pedersen, Joel A.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233
  • [27] Prion protein - tubulin interaction sites
    Osiecka, K.
    Nieznanska, H.
    Skowronek, K.
    Karolczak, J.
    Schneider, G.
    Nieznanski, K.
    FEBS JOURNAL, 2009, 276 : 158 - 158
  • [28] Reversing functional deficits in prion disease by targeting cellular prion protein
    不详
    NEUROSCIENTIST, 2007, 13 (04): : 302 - 302
  • [29] Decreased cell surface prion protein in mouse models of prion disease
    Griffin, Jennifer K.
    Terry, Linda A.
    Jackman, Roy
    Yousefi, Masoud
    Cashman, Neil R.
    NEUROREPORT, 2007, 18 (01) : 1 - 6
  • [30] The three-dimensional structure of prion protein: implications for prion disease
    Baldwin, MA
    James, TL
    Cohen, FE
    Prusiner, SB
    BIOCHEMICAL SOCIETY TRANSACTIONS, 1998, 26 (03) : 481 - 486